89bio Inc Stock Alpha and Beta Analysis
| ETNB Stock | USD 8.47 0.29 3.55% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as 89bio Inc. It also helps investors analyze the systematic and unsystematic risks associated with investing in 89bio over a specified time horizon. Remember, high 89bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to 89bio's market risk premium analysis include:
Beta 1.69 | Alpha 0.44 | Risk 6.06 | Sharpe Ratio 0.0473 | Expected Return 0.29 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
89bio |
89bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. 89bio market risk premium is the additional return an investor will receive from holding 89bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in 89bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate 89bio's performance over market.| α | 0.44 | β | 1.69 |
89bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of 89bio's Buy-and-hold return. Our buy-and-hold chart shows how 89bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.89bio Market Price Analysis
Market price analysis indicators help investors to evaluate how 89bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading 89bio shares will generate the highest return on investment. By understating and applying 89bio stock market price indicators, traders can identify 89bio position entry and exit signals to maximize returns.
89bio Return and Market Media
The median price of 89bio for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 8.03 with a coefficient of variation of 17.83. The daily time series for the period is distributed with a sample standard deviation of 1.53, arithmetic mean of 8.56, and mean deviation of 1.25. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/19/2024 |
2 | Disposition of 3821 shares by Mansbach Harry H of 89bio at 16.61 subject to Rule 16b-3 | 01/08/2025 |
3 | Disposition of 10963 shares by Le-nguyen Quoc of 89bio at 6.49 subject to Rule 16b-3 | 01/15/2025 |
4 | Acquisition by Mcwherter Charles of 5000 shares of 89bio at 6.55 subject to Rule 16b-3 | 01/21/2025 |
5 | Acquisition by Mcwherter Charles of 10000 shares of 89bio at 6.71 subject to Rule 16b-3 | 01/22/2025 |
6 | 89bio Inc Announces 250 Million Public Offering to Advance Clinical Developments | 01/27/2025 |
7 | Disposition of 1014 shares by Mansbach Harry H of 89bio at 15.46 subject to Rule 16b-3 | 01/28/2025 |
8 | Acquisition by Ra Capital Management, L.p. of 5714285 shares of 89bio at 8.75 subject to Rule 16b-3 | 01/30/2025 |
9 | Acquisition by Francis Sarena of 53750 shares of 89bio subject to Rule 16b-3 | 01/31/2025 |
10 | 89bio Inc Completes 287.5 Million Public Offering | 02/03/2025 |
11 | 89bio, Inc. Director Purchases 49,999,993.75 in Stock | 02/06/2025 |
12 | Disposition of 3817 shares by Mansbach Harry H of 89bio at 11.41 subject to Rule 16b-3 | 02/07/2025 |
13 | Disposition of 1050 shares by Mansbach Harry H of 89bio at 10.57 subject to Rule 16b-3 | 02/14/2025 |
14 | Acquisition by Babler Martin of 56400 shares of 89bio at 9.6 subject to Rule 16b-3 | 02/18/2025 |
15 | Wall Street Analysts See a 171.42 percent Upside in 89BIO Can the Stock Really Move This High | 02/20/2025 |
16 | 89bio Shares Down 9.1 percent Whats Next | 02/25/2025 |
17 | 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates | 02/27/2025 |
18 | IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty | 02/28/2025 |
19 | 89bio Inc to Participate in Leerink Partners Global Healthcare Conference | 03/03/2025 |
20 | Is 89BIO Stock Outpacing Its Medical Peers This Year | 03/06/2025 |
21 | Bears are Losing Control Over 89BIO , Heres Why Its a Buy Now | 03/12/2025 |
About 89bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including 89bio or other stocks. Alpha measures the amount that position in 89bio Inc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
89bio Upcoming Company Events
As portrayed in its financial statements, the presentation of 89bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, 89bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of 89bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of 89bio. Please utilize our Beneish M Score to check the likelihood of 89bio's management manipulating its earnings.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with 89bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out 89bio Backtesting, 89bio Valuation, 89bio Correlation, 89bio Hype Analysis, 89bio Volatility, 89bio History and analyze 89bio Performance. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
89bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.